G
ene transfer into hematopoietic stem cells (HSC) remains an important goal for the correction of metabolic, infectious, and oncologic disease. The capacity of stem cells to both self-renew and give rise to differentiated progeny makes them excellent targets for the long-term correction of genetic diseases. However, safe and effective gene transfer into this rare population of cells has remained elusive, and studies to date have been beset with problems of low transduction frequencies and subtherapeutic efficacy (1, 2) . In particular, the unexpected leukemic transformation of transduced cells in three patients treated with oncoretrovirus vectors for X-linked severe combined immunodeficiency (SCID) (3, 4) and the potential pathogenicity of other vector systems used underscore the need for continued exploration of alternate strategies for stem cell gene transfer.
Recombinant AAV (rAAV) vectors are proving to be safe and effective gene transfer vehicles that are neither pathogenic nor oncogenic. They transduce nondividing primary cells efficiently, are low in immunogenicity, and direct sustained transgene expression in vivo (5) (6) (7) . Infection with wild-type AAV is associated with inhibition of oncogenic transformation, and recent studies indicate that AAV inverted terminal repeats (ITR) may confer oncoprotection by inducing apoptosis in p53-deficient cells (8, 9) . Thus, rAAV vectors are good candidates for evaluation of safe and effective gene transfer into HSC.
Thus far, there have been no reports of in vivo evaluation of human HSCs, and reports of in vitro analyses of rAAV transduction have yielded conflicting results. Although several groups have observed successful rAAV-mediated gene transfer into human HSCs in vitro and in murine and non-human primate HSCs in vivo, others have reported difficulty in transducing HSCs (10) (11) (12) (13) (14) (15) . Apparent discrepancies have arisen primarily from short-term in vitro analyses of transduction by expression profiling and may be explained by the recent elucidation of several rate-limiting steps to initiation of transgene expression from rAAV, including nuclear entry, virus uncoating, and second-strand synthesis (16) (17) (18) (19) (20) (21) . However, most stem cell gene therapy applications require transgene expression in the differentiated progeny, rather than in stem cells. Therefore, despite delays in onset of expression, it remains important to assess the true efficacy of gene transfer into HSC in vivo with rAAV. And, species differences in properties of HSCs and vector tropism make it imperative to directly evaluate rAAV transduction of human HSC in vivo.
This study was designed to definitively address whether rAAV vectors can mediate gene transfer into true human HSC capable of long-term multilineage, serial engraftment in vivo using a transgene that permits functional endpoint evaluation. Results revealed that primitive human HSC capable of mediating serial engraftment in vivo were marked with rAAV at notably high frequencies in the absence of selective pressure. These results were further confirmed by serially evaluating rAAV marking of clonogenic cells with hematopoietic progenitor potential after primary and secondary transplantation. The rAAV vector encoded an antisense RNA complementary to a region of the HIV-1 LTR, including the TAR and polyadenylation regions (22) , and the efficacy of rAAV transduction was evidenced by the long-term induction of HIV-1 resistance in the progeny of transduced HSC. These findings provide proof of efficient AAV marking of human HSC in vivo.
Materials and Methods
Cell Isolation. Umbilical cord blood was collected at Huntington Memorial Hospital, and marrow samples were obtained from healthy donors by informed consent under City of Hope National Medical Center and Huntington Memorial Hospital Institutional Review Board-approved protocols. CD34 ϩ cells were isolated from mononuclear cells by two successive rounds of immunomagnetic selection by using CD34 ϩ isolation kits (Miltenyi Biotec, Auburn, CA) to a final purity of 96 -98%. CD34 ϩ CD38
Ϫ cells were sorted after staining with anti-CD34 and CD38 antibodies by using a Mo-Flo high-speed flow cytometer (Cytomation, Fort Collins, CO). The dimmest 20% of CD34 ϩ CD38 Ϫ cells were collected as the CD34 ϩ CD38 Ϫ population.
AAV Vectors. The construction, packaging, purification, and titration of rAAV vectors used in this study (Fig. 1A) have been described (12, 14) . Vector stocks were qualified and transduction confirmed by FISH analysis on CD34 ϩ cells (12) .
rAAV Transductions. Purified CD34 ϩ CD38 Ϫ cells were transduced at a particle multiplicity of infection 450-2,500 in complete Iscove's modified Dulbecco's medium with IL-3, IL6 (both at 10 ng͞ml; R & D Systems), and stem cell factor (1 ng͞ml; R & D Systems) and incubated in humidified CO 2 at 37°C (13, 15) . After 24 h, cells were washed three times before transplantation. 
CD34
ϩ CD38 Ϫ cells. Tissues were collected 5-26 weeks later. Total marrow cells (8-22 ϫ 10 6 ) from primary recipients with engraftment levels Ͼ10% were infused into secondary sublethally irradiated hosts. Secondary recipients were analyzed 6-11 weeks posttransplant.
Flow Cytometric Analysis. Human engraftment in NOD͞SCID mice was determined by flow cytometry after staining of marrow, spleen, and thymus cells with human-specific monoclonal antibodies and analysis of 50,000 events. Human-specific engraftment was evaluated after staining with anti-human CD45 antibody (Becton Dickinson). Human CD34 ϩ , CD19 ϩ , and CD14 ϩ or CD33 ϩ cells from primary and secondary recipients were analyzed and flow-sorted after staining with humanspecific antibodies. ϩ CD38 Ϫ cells (2,500-5,000) from each cord blood sample and 3-6 ϫ 10 5 total marrow cells from primary and secondary recipients were plated in CFU-C assays as described (13, 15) . After 2 weeks, individual colonies were picked for analysis.
Detection of rAAV Vector Sequences. rAAV sequences were initially evaluated by semiquantitative PCR and subsequently with quantitative real-time PCR (Taqman, Applied Biosystems) with vector-specific primers and probe (Fig. 1 A) . DNA from purified human lineages and colonies was amplified with vector-specific primers by using either semiquantitative PCR or real-time Taqman PCR analysis on a 7900HT Sequence Detection System (Applied Biosystems). The human single copy gene ApoB was used for cell number enumeration. Positive samples were scored based on a vector product quantity Ͼ1 and ApoB levels Ͼ1.
HIV Challenge Experiments. CD34
ϩ cells (5 ϫ 10 4 ) were plated in complete Iscove's modified Dulbecco's medium containing 1 ng͞ml stem cell factor, 10 ng͞ml IL-3, and 25 ng͞ml granulocyte͞ macrophage colony-stimulating factor, transduced overnight with rAAV, washed, and replated. Three to four weeks later, adherent macrophages were washed and infected overnight with HIV-1JR-FL at a multiplicity of infection of 0.01 as described (23) . Supernatants were collected at designated times and analyzed for HIV replication (23) by p24 ELISA assays (Coulter HIV-1 p24 antigen assay kit, Beckman Coulter).
Results
Engraftment of Human CD34 ؉ CD38 ؊ Cells in NOD͞SCID Mice After rAAV Transduction. To determine whether highly purified cord blood CD34 ϩ CD38 Ϫ cells could support long-term multilineage engraftment in immune-deficient NOD͞SCID mice after rAAV ( Fig. 1 A) transduction, we evaluated human hematopoietic engraftment 5-26 weeks posttransplantation. Input CD34 ϩ CD38 Ϫ cells were tested for purity and found to be free of contaminating differentiated cells (Fig. 4 , which is published as supporting information on the PNAS web site). Engraftment levels of 2-88.7% were observed (median 47%, n ϭ 50) as determined by the presence of human CD45 ϩ cells in the marrow over a 6-month period (Fig. 1B) . Engraftment was stable throughout the period of analysis, suggesting that the rAAVtransduced input cells were capable of supporting long-term engraftment.
Differentiated lympho-myeloid human cells and CD34 ϩ progenitors were detected in the marrow of primary transplant recipients up to 178 days posttransplant, the end of the experiment. Because the transplanted cells were free of contaminating mature cells, we concluded that the differentiated human cells were derived from the transplanted CD34 ( Fig. 1C) , indicating their capacity to both persist and͞or selfrenew in vivo.
CD45 ϩ human cells were detected in the spleen of transplant recipients (1.3-68.2%, n ϭ 48), after either direct homing after transplantation and͞or the trafficking from the marrow ( Fig.  1D ) with the majority (84.9 Ϯ 7.2%) being CD19 ϩ B lymphocytes ( Fig. 5 , which is published as supporting information on the PNAS web site). The overall level of splenic CD19 ϩ cells was found to increase slightly over the 6-month period of study (Fig.  1D) . These results indicate that input CD34 ϩ CD38 Ϫ cells were capable of both long-term engraftment and differentiation into lympho-myeloid lineages in vivo.
rAAV Marking of Human Hematopoietic Lineages in Primary Recipients. Human lineage-specific cells were flow sorted from transplant recipients and evaluated for rAAV transduction. Vectorspecific signals were never detected in mice transplanted with untransduced cord blood stem cells, and human Apo B-specific signals were never detected in untransplanted mouse marrow DNA, indicating the specificity of the assay. Twenty-eight of 32 (88%) recipients contained rAAV-marked cells in one or more lineage (Table 1) . However, not every lineage was marked in each mouse, possibly due to a lack of transduction of pluripotent stem cells in every case. Fourteen of 26 (54%) and 14 of 28 (50%) recipients with human CD19 ϩ cells in the marrow and spleen, respectively, had rAAV-marked B lymphocytes. Of 22 mice positive for human CD14 ϩ ͞CD33 ϩ cells, 64% were rAAV marked. Most importantly, 17 of 28 mice (61%) with human CD34 ϩ cells showed evidence of rAAV transduction. Overall, no preferential marking of any one lineage was observed, in concordance with true stem cell transduction. The frequency of rAAV-transduced cells remained similar over time, indicating that rAAV genomes persisted in a stable fashion within the dividing and differentiating progeny in the absence of selective pressure.
The frequency of rAAV-transduced cells in each lineage was quantitated by comparing the copy number of vector genomes to the total human cell equivalents as determined by the single copy gene ApoB (Table 2) . Of the 23 samples analyzed, 13 (57%) showed rAAV marking at a frequency Ͼ1͞1,000 cells, of which 5 (22% of the total) were marked at a frequency Ͼ1͞150 cells. Four of six CD34ϩ samples were marked at a frequency Ͼ1͞638 cells. All three samples analyzed for CD33ϩ and CD14ϩ myeloid cells showed a marking of Ն1͞800 cells, with 1 at a frequency of 1͞12 at 21 weeks posttransplantation. For the marrow B cell lineage, marking ranged from 1͞119 to 1͞20,724 cells. No decline in marking was observed over time after transplantation. These results demonstrate the following: (i) the ability of rAAV2 vectors to transduce CD34 ϩ CD38 Ϫ stem͞ progenitor cells capable of long-term lympho-myeloid reconstitution; (ii) the lack of any detrimental effects of rAAV transduction on stem cells with respect to the differentiation of any given lineage; and (iii) the long-term persistence of rAAVmarked CD34 ϩ cells in vivo.
rAAV Marking of Clonogenic Progenitor Cells in the Marrow of Transplant Recipients. To determine whether long-term SCID repopulating cells with hematopoietic progenitor potential were rAAV transduced, we evaluated myelo-erythroid progenitors derived from recipient marrow in colony forming assays (CFU-C) under conditions that exclusively support human hematopoiesis (Fig. 2) . After 2 weeks, 20 individual colonies representing granulocyte-macrophage (CFU-GM), burstforming unit-erythroid (BFU-E) and colony-forming unitgranulocyte-erythroid-macrophage-megakaryocyte (CFU-GEMM) were analyzed for rAAV and ApoB. Methylcellulose picked from intercolony spaces was routinely tested and found to be negative for rAAV, indicating that free vector DNA was not a contributing factor. rAAV transduction frequencies of CFU-C harvested from transplant recipients ranged from 11-100% (median 75%, n ϭ 36) over the 6-month period of analysis, with no appreciable drop in the frequency of transduced CFU-C over time. These findings indicate that rAAV vectors transduce primitive HSCs capable of clonogenic differentiation and longterm persistence in vivo.
rAAV Transduction of HSCs Capable of Serial Engraftment. To determine whether rAAV vectors are capable of transducing self-renewing HSCs, we tested the ability of transduced CD34 ϩ CD38 Ϫ cells to mediate reconstitution of mice serially transplanted with marrow from primary recipients. Analysis of secondary recipients at 6 -11 weeks posttransplantation revealed engraftment levels of 0.09 -46.88% (n ϭ 16) as evidenced by the presence of human CD45 ϩ cells in the marrow (Table 6 , which is published as supporting information on the PNAS web site). Twelve of 16 secondary mice showed 0.09 -2.2% human CD45 ϩ levels in the marrow whereas 4 mice displayed markedly higher engraftment at 14.63-46.88%. CD33 ϩ , CD19 ϩ , and CD34 ϩ cells were also detected in the secondary recipients, demonstrating the ability of rAAV2-transduced CD34 ϩ CD38 Ϫ cells to provide sustained multilineage hematopoietic reconstitution with no apparent lineagespecific tox icity in serially transplanted NOD͞SCID recipients. Antisense RNA expression was detected in the marrow of serially transplanted mice (Fig. 6 , which is published as supporting information on the PNAS web site), indicating that the vector genomes were transcriptionally active.
Frequency of rAAV Marking of Human Hematopoietic Lineages in
Secondary Recipients. Flow-sorted human cells from secondary recipients revealed rAAV marking in each lineage analyzed, with 13 of 16 (81.25%) secondary mice being marked in one or more lineage. Fifty-seven percent and 64% of the marrow and spleen CD19 ϩ B cells, respectively, showed rAAV marking. Sixty-seven percent of mice with CD33 ϩ myeloid cells displayed rAAV marking. Most significantly, 50% of secondary recipients with CD34 ϩ cells showed evidence of rAAV marking of this stem cell population.
Importantly, the frequency of rAAV transduction, was found to be markedly higher in secondary recipients than in primary recipients. Several secondary recipients showed rAAV marking frequencies Ն1͞10 cells for each lineage evaluated (Table 3) , with at least one sample of each lineage showing marking of 100%. A comparison of the median rAAV marking frequencies between primary and secondary recipients reveals a marked enrichment of transduced cells in secondary recipients for every lineage analyzed (Table 4 ) . The median marking frequency for all lineages was notably higher in the secondary recipients, with every lineage but one showing an enrichment of at least 1 log, indicating efficient transduction of primitive self-renewing stem cells by rAAV.
Notably, 12 of 30 recipients (40%) showed a marking frequency Ն1͞20 cells and 6 of 30 recipients (20%) showed rAAV marking at a frequency Ն1͞2 cells (Table 3) . For some recipients where insufficient cells were obtained for detailed analysis by lineage, total CD45 ϩ cells were tested, and transduction frequencies from 1͞2 to 1͞174 cells were observed. These results strongly suggest that rAAV vectors efficiently transduce primitive self-renewing CD34 ϩ CD38
Ϫ stem cells capable of supporting serial multilineage engraftment. The lack of observed pathogenicity suggests that rAAV-transduced stem cells contribute significantly to long-term genetically marked hematopoiesis with no adverse effects.
Serial Evaluation of rAAV Marking of Clonogenic Hematopoietic
Progenitor Cells in Primary and Secondary Recipients. To obtain independent confirmation of rAAV marking of stem cells, we serially evaluated rAAV transduction of clonogenic cells capable of differentiation in vitro from primary and secondary recipients. We sequentially compared the frequency of rAAV-marked human hematopoietic colonies derived from (i) the original CD34 ϩ CD38 Ϫ inocula, (ii) the marrow of primary recipients, and (iii) the marrow of the corresponding secondary recipients ( Table 5 ). The frequency of rAAV-marked clonogenic cells in the pretransplant inocula ranged from 55-100% (median: 95%). Clonogenic progenitors derived from the marrow of primary and secondary recipients showed rAAV marking ranging from 45-100% and 35-95%, respectively. These studies revealed that the majority of HSC isolated from primary and secondary recipients capable of clonal differentiation were marked with rAAV and that rAAV-transduced clonogenic progenitors either persist and͞or self-renew in vivo. Thus, these results provide functional confirmation of transduction of self-renewing multipotential HSC by rAAV. BM CD34  1a  1͞140  BM CD34  3a  1͞632  BM CD34  4a  1͞4,268  BM CD34  7a  1͞1  BM CD33  3a  1͞19  BM CD33  4a  1͞164  BM CD33  8a  1͞13  BM CD33  9a  1͞363  BM CD33  12a  1͞1  BM CD33  13a  1͞21, 
Inhibition of HIV-1 Replication in the Progeny of rAAV-Transduced
CD34 Cells. We next assessed whether rAAV transduction of CD34 ϩ cells would lead to evidence of therapeutic transgene function in the differentiated progeny. The therapeutic transgene in rCWRHIVAPAP encodes an antisense RNA complementary to the HIV-1 LTR (22) including the TAR and polyadenylation regions (Fig. 1 A) , a potent inhibitor of HIV-1 replication (22) . We tested the capacity of the macrophage progeny of transduced CD34 ϩ cells in long-term cultures to inhibit HIV-1 replication in the absence of selective pressure. CD34 ϩ cells were differentiated into macrophages before challenge with the macrophage-tropic HIV-1JRFL (23) at a multiplicity of 0.01. The rAAV transduction of these cells was tested in parallel experiments in the absence of HIV infection by FISH (12, 14) and long-term culture-initiating cell assays (ref. 14 and Table 7 , which is published as supporting information on the PNAS web site). No enrichment of transduced cells was performed before HIV-1 challenge. Antisense RNA expression was readily detected in transduced cultures by Northern blot analysis (Fig. 7 , which is published as supporting information on the PNAS web site). Notably, evaluation of HIV-1 replication as determined by levels of supernatant p24 in CD34 cultures obtained from four different donors revealed significant and sustained long-term inhibition of HIV-1 replication over the 48-to 64-day experimental period, as compared with either untransduced or control rAAV transduced cells (Fig. 3) . Thus, we conclude that rAAV-transduced CD34 ϩ cells differentiated into macrophages that expressed antisense RNA and exhibited resistance to HIV-1. The sustained and significant level of HIV-1 inhibition observed in every donor tested confirmed that stem cell transduction was efficient and functional.
Discussion
In this study, we showed efficient rAAV transduction of primitive, pluripotent, self-renewing human HSCs capable of supporting primary and secondary multilineage engraftment in vivo in the absence of selective pressure. rAAV-transduced stem cells differentiated into all expected lineages, including myeloid cells and B lymphocytes after transplantation, indicating their multipotential differentiation capacity. Transduced CD34 ϩ stem͞ progenitor cells were continuously detected throughout the analysis in primary and secondary recipients, indicating their long-term persistence and self-renewal capacity.
Most significantly, the frequency of rAAV marking was found to be higher in secondary recipients as compared with primary hosts, with 40% of samples being marked at a frequency Ͼ1 in 20 cells and 20%, showed a marking frequency Ն50%. Notably, 100% transduction was detected in some samples of every lineage evaluated. The enrichment of transduced cells observed in secondary recipients suggests that rAAV preferentially transduced primitive self-renewing stem cells. This result may be The median level of rAAV marking is shown for each group. Numbers in parentheses show total number of rAAV ϩ colonies over total number analyzed. attributable to the propensity of rAAV to efficiently transduce nondividing and quiescent cells (6) . It is also possible that the intracellular milieu of this population may promote integration due to the presence of higher levels of appropriate enzymes, such as those associated with DNA repair. Independent evidence of rAAV transduction of stem cells was obtained from the serial analysis of clonogenic human hematopoietic progenitors obtained from transplant recipients. These analyses showed that engrafting stem cells, which retained progenitor capacity, were efficiently marked with rAAV. The sustained high level marking of colony-forming cells in the marrow of primary and secondary recipients confirmed both the self-renewal and multipotential properties of rAAV-transduced cells.
The overall frequency of marked progeny did not decline over time, indicating that the vector genomes were most likely chromosomally integrated. rAAV genomes are known to initially exist as episomes (24, 25 ); however, a low level of integration has consistently been reported (12, (26) (27) (28) . We and others have previously demonstrated rAAV integration in CD34 ϩ cells in vitro by Southern and FISH analyses (12) . It is likely that early after transduction, rAAV genomes exist in an episomal form, and subsequently integration proceeds in those cells that possess the requisite enzymes. In the dividing progeny of transduced stem cells, episomal forms of the vector genomes were likely lost during mitosis, with only those cells with integrated rAAV contributing to long-term rAAV-marked hematopoiesis. Thus the rAAV-transduced cells detected in vivo are most likely derived from a fraction of stem cells in which rAAV genomes underwent chromosomal integration.
Recent evidence for rAAV transduction of stem cells has been forthcoming from other systems as well. Song et al. (29) showed repopulation of hepatectomized murine livers with rAAVtransduced oval cells (29) , which possess progenitor activity and display CD34 and CD45 surface markers similar to HSC. rAAV transduction of marrow-derived mesenchymal stem cells (30, 31) , alveolar stem cells (32) , neural progenitor cells (33) , and embryonic stem cells (34) has been demonstrated. If primitive quiescent HSCs were more efficiently transduced than dividing progenitors, higher marking frequencies in secondary recipients would be expected, as observed in this study.
Notably, the macrophage progeny of CD34 ϩ cells transduced with the rAAV vector encoding antisense RNA complementary to the HIV-1 LTR (23) exhibited both transgene expression and long-term inhibition of HIV-1 replication. Sustained and significant inhibition of HIV-1 replication was observed in every donor tested in the absence of prior enrichment of transduced cells. It is likely that HIV challenge itself exerted selective pressure and allowed the preferential survival of transduced cells. Although initiation of transgene expression may be delayed after rAAV2 transduction, it is clear that rAAV genomes are capable of persisting in stem cells and being transmitted to their progeny in a functionally effective manner. It is also likely that the use of AAV capsids of novel serotypes may lead to more rapid onset of transgene expression as noted with AAV8 in the liver (21, 35) .
Our study clearly demonstrates efficient gene transfer by rAAV2 vectors into primitive human HSCs capable of mediating long-term in vivo multilineage engraftment, as well as serial repopulation of secondary recipients. Our results suggest that self-renewing pluripotential HSCs are preferentially marked with rAAV2 and that the progeny of transduced HSCs express functional transgenes. The efficiency of rAAV-mediated gene transfer into human HSCs, taken together with the safety record of rAAV, the lack of association with oncogenesis, and possible anti-oncogenic effects of AAV ITRs (9), may form the basis for safe and effective ex vivo gene therapy of the hematopoietic system with rAAV.
